Quick Answer
Trevi Therapeutics, Inc. reported Net Income of -$42.76 million for fiscal year 2025.
Trevi Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$42.76M +10.8% |
-$47.91M -64.8% |
-$29.07M +0.3% |
-$29.15M +14.1% |
-$33.94M -3.6% |
-$32.76M -25.8% |
| Diluted EPS | -$0.32 +31.9% |
-$0.47 -62.1% |
-$0.29 +35.6% |
-$0.45 +69.8% |
-$1.49 | — |
| Total Assets | $193.44M +74.4% |
$110.90M +24.0% |
$89.40M -27.3% |
$123.02M +219.7% |
$38.48M -18.4% |
$47.13M -21.4% |
| Cash and Equivalents | $18.91M -44.5% |
$34.10M +5.2% |
$32.40M +157.3% |
$12.59M -65.8% |
$36.83M -18.2% |
$45.00M -21.5% |
| Stockholders Equity | $183.24M +83.9% |
$99.64M +20.7% |
$82.55M -23.2% |
$107.46M +529.3% |
$17.07M -37.4% |
$27.28M -50.0% |
| R&D Expense | $33.48M -15.0% |
$39.38M +66.3% |
$23.68M +19.4% |
$19.83M -13.7% |
$22.98M +2.9% |
$22.33M +15.5% |
| Operating Income | -$49.33M +4.3% |
-$51.52M -51.9% |
-$33.92M -13.4% |
-$29.91M +7.9% |
-$32.48M +0.0% |
-$32.49M -21.9% |
| Shares Outstanding | 128.31M +37.1% |
93.60M +37.1% |
68.28M +13.9% |
59.94M +110.3% |
28.51M +53.7% |
18.55M +4.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$11.80M | +10.9% | +4.1% |
| Diluted EPS | September 30, 2025 | -$0.08 | +38.5% | +11.1% |
| Total Assets | September 30, 2025 | $199.36M | +189.3% | -4.3% |
| Cash and Equivalents | September 30, 2025 | $56.87M | +254.3% | -51.4% |
| Stockholders Equity | September 30, 2025 | $189.79M | +221.8% | -4.4% |
| R&D Expense | September 30, 2025 | $10.09M | -10.1% | +7.4% |
| Operating Income | September 30, 2025 | -$13.92M | +1.2% | -1.4% |
| Shares Outstanding | September 30, 2025 | 128.22M | +69.9% | +5.3% |
- Trevi Therapeutics, Inc. reported Net Income of -$42.76 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +10.8% in Net Income compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +31.9% in Diluted EPS compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Total Assets of $193.44 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +74.4% in Total Assets compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Cash and Equivalents of $18.91 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed a decrease of -44.5% in Cash and Equivalents compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Stockholders Equity of $183.24 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +83.9% in Stockholders Equity compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported R&D Expense of $33.48 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed a decrease of -15.0% in R&D Expense compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Operating Income of -$49.33 million for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +4.3% in Operating Income compared to the prior fiscal year.
- Trevi Therapeutics, Inc. reported Shares Outstanding of 128.31 million shares for fiscal year 2025.
- Trevi Therapeutics, Inc. showed an increase of +37.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: